Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTP1DC)

• Drug Name: Irbesartan Drug Info
• Synonyms: irbesartan; 138402-11-6; Aprovel; Avapro; Karvea; SR-47436; BMS-186295; BMS 186295; Irbesartan [USAN:INN]; SR 47436; UNII-J0E2756Z7N; CHEMBL1513; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[44]non-8-en-6-one; CHEBI:5959; C25H28N6O; YOSHYTLCDANDAN-UHFFFAOYSA-N; J0E2756Z7N; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[44]non-1-en-4-one; NCGC00095122-01; AK-57149; DSSTox_CID_3169; Aprovel; Irbesarran; Irbetan; Lrbesartan; BMS Brand of Irbesartan; Bristol Myers Brand of Irbesartan; SanofiWinthrop Brand of Irbesartan; Aprovel (TN); Avalide (TN); Avapro (TN); Karvea (TN); Irbesartan (JAN/USAN/INN); BMS-186295, SR-47436,Aprovel, Karvea, Irbesartan; 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(44)non-1-en-4-one; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[44]non-1-en-4-one; 2-butyl-3-[ p-(o-1 H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one; 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[44]non-1-en-4-one; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one; [3H]irbesartan
• Therapeutic Class: Antihypertensive Agents
• Cross-matching ID:
  PubChem CID: 3749
  ChEBI ID: CHEMBL1513
  CAS Number: CAS 138402-11-6
  TTD Drug ID: D00JAU
  VARIDT Drug ID: DR00482
  INTEDE Drug ID: DR0879
  ACDINA Drug ID: D00330

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Cell cycle	2.21	0.00e+0	110/124 (88.71%)	E2F2;CCNB2;SFN;...
Oocyte meiosis	1.94	2.44e-2	90/129 (69.77%)	CCNB2;MAD2L1;ITPR3;...
DNA replication	1.82	4.23e-2	34/36 (94.44%)	MCM3;RFC2;PRIM1;...
Steroid hormone biosynthesis	-1.71	4.23e-2	43/61 (70.49%)	COMT;CYP19A1;CYP3A7;...
Viral myocarditis	-1.72	4.32e-2	53/60 (88.33%)	RAC1;EIF4G1;CAV1;...
Glycine, serine and threonine metabolism	-1.73	4.00e-2	31/40 (77.5%)	GATM;DAO;GNMT;...
Mitophagy	-1.78	2.69e-2	56/68 (82.35%)	RELA;CALCOCO2;MRAS;...
Epithelial cell signaling in Helicobacter pylori infect...	-1.80	2.35e-2	62/70 (88.57%)	ATP6V0E2;CDC42;CXCR2;...
beta-Alanine metabolism	-1.82	2.16e-2	25/30 (83.33%)	AOC2;HADHA;HIBCH;...
Primary bile acid biosynthesis	-1.92	2.55e-3	15/17 (88.24%)	CYP7B1;SCP2;CYP27A1;...
Metabolism of xenobiotics by cytochrome P450	-1.94	2.92e-3	49/77 (63.64%)	GSTA3;CYP2C9;CYP3A4;...
Drug metabolism	-1.95	1.70e-3	78/151 (51.66%)	CYP2B6;ADH6;IMPDH2;...
Allograft rejection	-1.96	2.04e-3	32/38 (84.21%)	GZMB;IL12B;IFNG;...
Tryptophan metabolism	-2.06	0.00e+0	35/42 (83.33%)	DLST;HADHA;KMO;...
Retinol metabolism	-2.07	0.00e+0	41/68 (60.29%)	CYP3A7;CYP2A6;ADH7;...
Antigen processing and presentation	-2.10	0.00e+0	60/78 (76.92%)	NFYB;KIR3DL1;CANX;...
Autoimmune thyroid disease	-2.11	0.00e+0	46/53 (86.79%)	IL4;IFNA5;TG;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 2.22uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 2.22uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 2.22uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 2.22uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 2.22uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼